Sarepta Therapeutics, Inc. SRPT 深 滬
等待開盤 09-23 09:30:00 美东时间
20.81
+0.670
+3.33%
華盛通- 最 高21.185
- 今 開20.46
- 成交量 219.30万股
- 最 低 20.19
- 昨 收 20.14
- 總市值 21.98亿
- 52周最高 25.32
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 14.68
- 委 比 11.01%
- 總股本 1.06亿
- 歷史最高 181.83
- 量 比 0.70
- 振 幅 4.94%
- 歷史最低 0.433
- 每 手 1
- 風險率 2.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease development: how...
09-21 02:57
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG’s (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1). Impact Of Novartis Phase 3 Trial Results The study did not demonstrate statistically signifi...
09-09 01:47
Biggest stock movers Tuesday: ZIM, NVS, and more
Stock futures edged lower Tuesday morning as Brent crude holds above $98 a barrel amid Iranian threats against Gulf oil and gas infrastructure. Here are some of Tuesday's biggest stock movers: Biggest...
09-08 17:23
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Swiss drugmaker Novartis' (NVS) shares fell 13% in premarket trading on Tuesday following news that its late-stage trial for muscle-wasting drug candidate del-desiran failed to meet primary endpoints....
09-08 16:56
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Shares of iSpecimen Inc (NASDAQ:ISPC) rose sharply in pre-market trading after the company announced plans to acquire Foldlab AI assets for $4.5 million, including AI models, software and intellectual property. iSpecimen shares jumped 27.9% to $1.97 in pre-market trading. Here are some other stocks ...
09-08 16:44
Most shorted stocks on Wall Street
As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% ...
09-02 22:28
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings of $2.02 per share from the same period last year. The company reported quarterly sales of $401.300 m...
08-06 04:14
Sarepta taps Michael Severino as CEO
Sarepta Therapeutics (SRPT) has appointed Michael Severino as chief executive officer, effective July 28, 2026. Severino, the former CEO of Tessera Therapeutics, will also join Sarepta's board of dire...
07-27 20:40
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Boa...
07-27 20:37
Roche jumps despite reiterating 2026 outlook
Roche (RHHBY) (RHHBF) shares closed ~5% higher in Zurich on Thursday, recording its best single-day gain since November, even as the Swiss drugmaker reaffirmed its 2026 outlook with its financials for...
07-24 00:27
